Under the collaboration, the two companies will work together on a phase two clinical trial to evaluate the efficacy of centanafadine extended-release capsules on adults with major depressive disorder, according to a Feb. 1 release from Verily.
The study, dubbed Juniper, will recruit 336 participants.
The move comes after Verily announced it would be sunsetting some of its healthcare projects and restructuring its leadership to focus on remote patient monitoring for heart failure and microneedles for drug delivery.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
